Literature DB >> 7826793

Predictive factors of hyperfibrinolytic activity during liver transplantation in cirrhotic patients.

A Steib1, N Gengenwin, G Freys, K Boudjema, S Levy, J C Otteni.   

Abstract

Hyperfibrinolytic activity occurs frequently during liver transplantation in cirrhotic patients. In order to identify those patients at high risk for increased intraoperative blood loss before operation, we determined predictive indicators of hyperfibrinolysis. We studied 56 cirrhotic patients undergoing liver transplantation with the same anaesthetic procedure and transfusion regimen. The preoperative coagulation patterns of the 11 patients who experienced acute intraoperative hyperfibrinolytic activity were compared with those of the 45 patients who did not suffer this complication. Before surgery, patients with intraoperative hyperfibrinolysis had decreased prothrombin time (PT) and euglobulin lysis time (ELT), and increased thrombin time (TT) and fibrinogen degradation products (FDP), whereas alpha angle and maximum amplitude (MA) were reduced on thrombelastography. Stepwise multivariate analysis disclosed three components which were significantly linked with occurrence of hyperfibrinolysis: TT, FDP and MA. Their sensitivity, specificity, positive and negative predictive values demonstrated that patients with FDP > or = 48 mg litre-1 and MA < or = 35 mm before incision had 100% probability of developing hyperfibrinolytic activity during transplantation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7826793     DOI: 10.1093/bja/73.5.645

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  8 in total

Review 1.  New insights into the coagulopathy of liver disease and liver transplantation.

Authors:  M Senzolo; P Burra; E Cholongitas; A-K Burroughs
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

2.  Preoperative Thromboelastometry as a Predictor of Transfusion Requirements during Adult Living Donor Liver Transplantation.

Authors:  Nirmeen Fayed; Wessam Mourad; Khaled Yassen; Klaus Görlinger
Journal:  Transfus Med Hemother       Date:  2015-03-31       Impact factor: 3.747

3.  High circulating D-dimers are associated with ascites and hepatocellular carcinoma in liver cirrhosis.

Authors:  Aldo Spadaro; Vincenza Tortorella; Carmela Morace; Agostino Fortiguerra; Paola Composto; Caterina Bonfiglio; Angela Alibrandi; Carmelo Luigiano; Giuseppe De Caro; Antonino Ajello; Oscar Ferrau; Maria-Antonietta Freni
Journal:  World J Gastroenterol       Date:  2008-03-14       Impact factor: 5.742

Review 4.  Transfusion and coagulation management in liver transplantation.

Authors:  Ben Clevenger; Susan V Mallett
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

5.  Epsilon-aminocaproic acid improves postrecirculation hemodynamics by reducing intraliver activated protein C consumption in orthotopic liver transplantation.

Authors:  H Y Kong; X H Wen; S Q Huang; S M Zhu
Journal:  World J Surg       Date:  2014-01       Impact factor: 3.352

6.  Iodinated contrast does not alter clotting dynamics in acute ischemic stroke as measured by thromboelastography.

Authors:  Mark M McDonald; Joancy M Archeval-Lao; Chunyan Cai; Hui Peng; Navdeep Sangha; Stephanie A Parker; Jeremy Wetzel; Stephen A Riney; Matt F Cherches; Greer J Guthrie; Tiffany C Roper; Jorge F Kawano-Castillo; Renga Pandurengan; Mohammad H Rahbar; James C Grotta
Journal:  Stroke       Date:  2013-12-26       Impact factor: 7.914

Review 7.  Thrombelastography (TEG®): practical considerations on its clinical use in trauma resuscitation.

Authors:  Luis Teodoro da Luz; Bartolomeu Nascimento; Sandro Rizoli
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2013-04-16       Impact factor: 2.953

Review 8.  Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis.

Authors:  Ingrid Pabinger; Dietmar Fries; Herbert Schöchl; Werner Streif; Wolfgang Toller
Journal:  Wien Klin Wochenschr       Date:  2017-04-21       Impact factor: 1.704

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.